Antonio Zorzano

Antonio Zorzano

Auto-generated profile, based on publicly available information

Antonio Zorzano

Institute for Research in Biomedicine (IRB), Barcelona, Spain

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2005 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
SPSara Pich
Sara Pich
DBDaniel Bach
Daniel Bach
PBPaz Briones
Paz Briones
Marc LiesaMarc Liesa
Marc Liesa
MCMarta Camps
Marta Camps
AZAntonio Zorzano
Antonio Zorzano
Mitofusin-2 (Mfn2) is a mitochondrial membrane protein that participates in mitochondrial fusion in mammalian cells and mutations in the Mfn2 gene cause Charcot–Marie–Tooth neuropathy type 2A. Here, we show that Mfn2 loss-of-function inhibits pyruvate, glucose and fatty acid oxidation and reduces mitochondrial membrane potential, whereas Mfn2 gain-of-function increases glucose oxidation and mitochondrial membrane potential. As to the mechanisms involved, we have found that Mfn2 loss-of-function represses nuclear-encoded subunits of OXPHOS complexes I, II, III and V, whereas Mfn2 overexpression induced the subunits of complexes I, IV and V. Obesity-induced Mfn2 deficiency in rat skeletal muscle was also associated with a decrease in the subunits of complexes I, II, III and V. In addition, the effect of Mfn2 overexpression on mitochondrial metabolism was mimicked by a truncated Mfn2 mutant that is inactive as a mitochondrial fusion protein. Our results indicate that Mfn2 triggers mitochondrial energization, at least in part, by regulating OXPHOS expression through signals that are independent of its role as a mitochondrial fusion protein.

15 February 2001 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
MFMariona Font
Mariona Font
LFLídia Feliubadaló
Lídia Feliubadaló
XEXavier Estivill
Xavier Estivill
VNVirginia Nunes
Virginia Nunes
EGEliahu Golomb
Eliahu Golomb
MPManuel Palacín
Manuel Palacín
Cystinuria (OMIM 220100) is a common recessive disorder of renal reabsorption of cystine and dibasic amino acids that results in nephrolithiasis of cystine. Mutations in SLC3A1, which encodes rBAT, cause Type I cystinuria, and mutations in SLC7A9, which encodes a putative subunit of rBAT (bo,+AT), cause non-Type I cystinuria. Here we describe the genomic structure of SLC7A9 (13 exons) and 28 new mutations in this gene that, together with the seven previously reported, explain 79% of the alleles in 61 non-Type I cystinuria patients. These data demonstrate that SLC7A9 is the main non-Type I cystinuria gene. Mutations G105R, V170M, A182T and R333W are the most frequent SLC7A9 missense mutations found. Among heterozygotes carrying these mutations, A182T heterozygotes showed the lowest urinary excretion values of cystine and dibasic amino acids. Functional analysis of mutation A182T after co-expression with rBAT in HeLa cells revealed significant residual transport activity. In contrast, mutations G105R, V170M and R333W are associated to a complete or almost complete loss of transport activity, leading to a more severe urinary phenotype in heterozygotes. SLC7A9 mutations located in the putative transmembrane domains of bo,+AT and affecting conserved amino acid residues with a small side chain generate a severe phenotype, while mutations in non-conserved residues give rise to a mild phenotype. These data provide the first genotype–phenotype correlation in non-Type I cystinuria, and show that a mild urinary phenotype in heterozygotes may associate with mutations with significant residual transport activity.

21 November 2007 in PLOS ONE
Verified
Journal Article
Open access
PDF file
BBBernhard G Baumgartner
Bernhard G Baumgartner
MOMeritxell Orpinell
Meritxell Orpinell
JDJordi Duran
Jordi Duran
VRVicente Ribas
Vicente Ribas
HBHans E Burghardt
Hans E Burghardt
AZAntonio Zorzano
Antonio Zorzano
Diabetes is characterized by reduced thyroid function and altered myogenesis after muscle injury. Here we identify a novel component of thyroid hormone action that is repressed in diabetic rat muscle. We have identified a gene, named DOR, abundantly expressed in insulin-sensitive tissues such as skeletal muscle and heart, whose expression is highly repressed in muscle from obese diabetic rats. DOR expression is up-regulated during muscle differentiation and its loss-of-function has a negative impact on gene expression programmes linked to myogenesis or driven by thyroid hormones. In agreement with this, DOR enhances the transcriptional activity of the thyroid hormone receptor TRα1. This function is driven by the N-terminal part of the protein. Moreover, DOR physically interacts with TR α1 and to T3-responsive promoters, as shown by ChIP assays. T3 stimulation also promotes the mobilization of DOR from its localization in nuclear PML bodies, thereby indicating that its nuclear localization and cellular function may be related. Our data indicate that DOR modulates thyroid hormone function and controls myogenesis. DOR expression is down-regulated in skeletal muscle in diabetes. This finding may be of relevance for the alterations in muscle function associated with this disease.

1 July 2006 in IUBMB Life
Verified
Journal Article
Open access
PDF file
AZAntonio Zorzano
Antonio Zorzano
SPSara Pich
Sara Pich
IUBMB Life is the flagship journal of the International Union of Biochemistry and Molecular Biology and is devoted to the rapid publication of the most novel and significant short articles, reviews and papers in the broadly defined fields of biochemistry, molecular biology, cell biology, and molecular medicine.

31 January 2013 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
José María Moreno-NavarreteJosé María Moreno-Navarrete
José María Moreno-Navarrete
FOFrancisco Jose Ortega
Francisco Jose Ortega
MSMiguel Ángel Sánchez-Garrido
Miguel Ángel Sánchez-Garrido
MSMònica Sabater
Mònica Sabater
WRWifredo Ricart
Wifredo Ricart
JFJosé M. Fernandez-Real
José M. Fernandez-Real

14 October 2008 in Clinical Endocrinology
Verified
Journal Article
Closed access
PDF file
HBHans Burghardt
Hans Burghardt
ALAbel López‐Bermejo
Abel López‐Bermejo
BBBernhard Baumgartner
Bernhard Baumgartner
LILourdes Ibáñez
Lourdes Ibáñez
Vendrell JoanVendrell Joan
Vendrell Joan
AZAntonio Zorzano
Antonio Zorzano